T. Rowe Price Associates’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $716K | Sell |
153,271
-23,122
| -13% | -$108K | ﹤0.01% | 2130 |
|
|
2025
Q1 | $969K | Buy |
176,393
+5,911
| +3% | +$32.5K | ﹤0.01% | 1972 |
|
|
2024
Q4 | $578K | Buy |
170,482
+9,506
| +6% | +$32.2K | ﹤0.01% | 2221 |
|
|
2024
Q3 | $459K | Buy |
160,976
+30,008
| +23% | +$85.6K | ﹤0.01% | 2281 |
|
|
2024
Q2 | $295K | Buy |
130,968
+5,333
| +4% | +$12K | ﹤0.01% | 2420 |
|
|
2024
Q1 | $278K | Buy |
125,635
+10,632
| +9% | +$23.5K | ﹤0.01% | 2471 |
|
|
2023
Q4 | $271K | Buy |
115,003
+2,180
| +2% | +$5.14K | ﹤0.01% | 2422 |
|
|
2023
Q3 | $210K | Buy |
112,823
+2,404
| +2% | +$4.48K | ﹤0.01% | 2483 |
|
|
2023
Q2 | $290K | Sell |
110,419
-12,560
| -10% | -$33K | ﹤0.01% | 2377 |
|
|
2023
Q1 | $201K | Hold |
122,979
| – | – | ﹤0.01% | 2527 |
|
|
2022
Q4 | $164K | Buy |
122,979
+19,370
| +19% | +$25.8K | ﹤0.01% | 2589 |
|
|
2022
Q3 | $162K | Buy |
103,609
+66,975
| +183% | +$105K | ﹤0.01% | 2609 |
|
|
2022
Q2 | $56K | Buy |
36,634
+12,634
| +53% | +$19.3K | ﹤0.01% | 2836 |
|
|
2022
Q1 | $61K | Buy |
24,000
+11,300
| +89% | +$28.7K | ﹤0.01% | 2900 |
|
|
2021
Q4 | $37K | Sell |
12,700
-51,700
| -80% | -$151K | ﹤0.01% | 2936 |
|
|
2021
Q3 | $158K | Buy |
64,400
+7,500
| +13% | +$18.4K | ﹤0.01% | 2764 |
|
|
2021
Q2 | $232K | Buy |
56,900
+7,433
| +15% | +$30.3K | ﹤0.01% | 2665 |
|
|
2021
Q1 | $223K | Buy |
+49,467
| New | +$223K | ﹤0.01% | 2650 |
|